Catalog No.
Product Name
Application
Product Information
Citations
-
Adenosine A2A Antagonist
MSX3 is a potent antagonist of the adenosine A2A receptor, demonstrating significant activity in modulating neuropharmacological responses. This compound has shown efficacy in reversing the effects of dopamine antagonism, specifically counteracting the impacts of Haloperidol on effort-related decision-making tasks in T-maze cost/benefit assessments. MSX3 is valuable for research exploring the roles of adenosine signaling in neurological disorders and the interplay between dopaminergic and adenosinergic systems. -
A2 AR Agonist
YT 146 is a potent agonist of the A2 adenosine receptor (A2 AR). It induces concentration-dependent accumulation of cyclic AMP, with an EC50 value of 1.5 nM. This compound exhibits cardioprotective effects, making it valuable for research into cardiovascular health and related therapeutic applications. -
A3AR Allosteric Enhancer
LUF6096 is a potent allosteric enhancer of the adenosine A3 receptor (A3AR), capable of enhancing agonist binding without exhibiting significant orthosteric affinity for any adenosine receptors. This compound demonstrates protective effects in myocardial ischemia/reperfusion injury, making it valuable for research in cardiovascular therapeutics and receptor biology. Its unique mechanism offers an innovative approach to modulating A3AR activity in related studies. -
Adenosine Receptor Antagonist
M1069 free base is a selective and orally active dual antagonist of the A2A and A2B adenosine receptors, demonstrating over 100-fold selectivity against A1 and A3 receptors. This compound counteracts the immune-suppressive effects of adenosine, making it valuable for research applications focused on cancer immunotherapy and potential anti-tumor activity. M1069's mechanism can inform studies aimed at understanding adenosine signaling pathways and their role in tumor microenvironments. -
A3AR Antagonist
A3AR Antagonist 4 is a potent antagonist of the A3 adenosine receptor, exhibiting Ki values of 30.8 nM for the human A3 receptor and 203 nM for the human A1 receptor. This compound is primarily utilized in research focused on cerebral ischemia, enabling investigations into its role in neuroprotection and inflammatory pathways associated with this condition. Through its selective blockade, A3AR Antagonist 4 serves as an important tool for elucidating the therapeutic potential of adenosine receptor modulation in neurological studies. -
Stable Isotope
Theobromine-d6 is a deuterium-labeled derivative of theobromine, a methylxanthine compound primarily found in cacao beans. This isotopically enriched reagent can be utilized in studies focusing on adenosine receptor A1 (AR1) signaling inhibition. It is suitable for quantitative analysis in metabolic studies and the investigation of the pharmacokinetics of theobromine and related compounds. -
Adenosine Receptor antagonist
A1/A3 AR antagonist 2 is an antagonist of the adenosine A1 and A3 receptors. This compound exhibits significant potential in studying neurological inflammatory diseases by modulating adenosine signaling pathways. Its application in research may enhance the understanding of the pathophysiology of various neurological disorders and the development of targeted therapies. -
A1AR Allosteric Modulator
TRR469 is a positive allosteric modulator of the A1 adenosine receptor (A1AR). It enhances the binding affinity of 2-chloro N(6)-cyclopentyladenosine (CCPA) for A1AR, thereby increasing the recognition of receptors by the agonist radioligand [³H]-CCPA. TRR469 demonstrates significant efficacy in preclinical models of anxiety and pain, making it a valuable tool for investigating anxiety disorders and developing pain management strategies. -
Adenosine Receptor Antagonist
Bamifylline hydrochloride is a xanthine derivative that functions as a selective antagonist of the adenosine A1 receptor. This compound exhibits significant biological activity in modulating adenosine signaling pathways, which may impact various physiological processes. Bamifylline hydrochloride is primarily utilized in research to explore its potential therapeutic effects on cardiovascular and respiratory disorders. -
A1AR Antagonist
A1AR antagonist 5 is a potent and selective antagonist of the A1 adenosine receptor (A1AR), exhibiting a pIC50 of 5.83 and a pKi of 6.11. This compound is valuable for research applications focused on the modulation of adenosine signaling pathways, cardiovascular protection, and neuroprotection. Its specificity makes it an ideal tool for investigating the therapeutic potential of A1AR antagonism in various disease models. -
A1R/A3R Dual Antagonist
A1/A3 AR Antagonist 3 is a dual antagonist targeting A1 and A3 adenosine receptors, exhibiting high affinity in the low-micromolar to low-nanomolar range. This compound is instrumental in researching chronic heart diseases, facilitating the exploration of mechanisms involved in cardiac function and pathology. Its selective inhibition of A1 and A3 receptors may provide insights into potential therapeutic strategies for related cardiovascular disorders. -
A3AR Agonist
MRS3558 is a potent and selective agonist of the A3 adenosine receptor (A3AR), exhibiting Ki values of 0.6 nM for human receptors and 0.9 nM for rat receptors. This compound is valuable for investigating the role of A3AR in neuropathic pain pathways and anesthetic responses. Its high selectivity and potency make it an essential tool for research in receptor pharmacology and therapeutic development. -
A2A Adenosine Antagonist
ST 1535 is a potent, orally active antagonist of the A2A adenosine receptor. It exhibits significant antiparkinsonian activity as well as antitremorigenic effects, making it a valuable tool for research on Parkinson’s disease. Its mechanism of action and biological activity provide insights into adenosine receptor modulation and its implications in neurodegenerative disorders. -
hA2AAR Antagonist
hA2AAR antagonist 1 is a highly selective antagonist for the human adenosine A2A receptor (hA2AAR) with a Ki value of 5 nM. This compound is instrumental for research in immune-oncology, providing valuable insights into the modulation of immune responses through adenosine signaling pathways. Its specificity and potency make it a suitable tool for studying cancer immunotherapy and related biological processes. -
hA3AR Inhibitor
PSB-10 hydrochloride is a highly selective antagonist of the human adenosine A3 receptor (hA3AR), demonstrating a Ki value of 0.44 nM. It exhibits over 800-fold selectivity for hA3AR compared to other adenosine receptor subtypes, including rA1, rA2A, hA1, hA2A, and hA2B, with respective Ki values of 805, 6040, 1700, 2700, and 30000 nM. This compound has been shown to induce thermal hyperalgesia in mouse models, making it valuable for exploring pain pathways and adenosine receptor signaling in research. -
A1AR Antagonist
A1AR antagonist 4 is a potent and selective A1 adenosine receptor (A1AR) antagonist, exhibiting a pIC50 of 5.51 and a pKi of 6.29. This compound is valuable for studying the role of A1AR in various physiological processes and diseases. Its application extends to research on cardiovascular functions, neuroprotection, and metabolic regulation, making it a crucial tool for advancing understanding in these fields. -
A3 Adenosine Receptor Antagonist
PSB11 hydrochloride is a selective antagonist of the A3 adenosine receptor, exhibiting a high affinity with a Ki value of 2.3 nM. This compound demonstrates reverse excitatory activity, making it a valuable tool for investigating the physiological and pharmacological roles of the A3 receptor. It is suitable for research applications involving modulation of adenosine signaling pathways and its implications in various biological processes. -
Adenosine Receptor Antagonist
Xanthine amine congener is a non-selective antagonist of adenosine receptors. This compound is known to induce convulsions in murine models, making it a valuable tool for studying the physiological and pharmacological roles of adenosine signaling in the central nervous system. It can be utilized in research applications focused on neurological disorders and receptor pharmacology. -
Adenosine Receptor Antagonist
Taminadenant mesylate is a potent antagonist of the adenosine A2A receptor, exhibiting significant anti-tumor properties. It selectively binds to A2A receptors on T lymphocytes, thereby alleviating adenosine/A2A-mediated inhibition and promoting T cell-mediated immune responses against cancer cells. Additionally, Taminadenant mesylate has demonstrated efficacy in reducing hyperactivity in Parkinson's disease models by inhibiting L-DOPA-induced dyskinesias, making it a valuable reagent for research in both oncology and neuropharmacology. -
A3 Adenosine Receptor Agonist
N6-Benzyl-5'-ethylcarboxamido adenosine is a selective agonist for the A3 adenosine receptor. This compound exhibits biological activity by enhancing A3 receptor signaling, which is implicated in various physiological processes, including anti-inflammatory responses and cardioprotection. It is valuable for research applications exploring the role of A3 receptors in pharmacology and disease models. -
Adenosine Receptor Agonist
hA3AR agonist 1 is a potent agonist of the human A3 adenosine receptor (hA3AR), exhibiting a Ki value of 2.40 nM. This compound is valuable for studying the roles of hA3AR in various physiological processes and its potential therapeutic applications in areas such as inflammation and cancer. Researchers can utilize hA3AR agonist 1 to investigate receptor signaling pathways and to assess the compound's effects in relevant biological assays. -
A3AR Agonist
A3AR agonist 3 is a selective agonist of the A3 adenosine receptor (A3AR), exhibiting Ki and EC50 values of 2.27 nM and 0.20 nM for human A3 receptors and cAMP modulation, respectively. This compound is valuable for studies investigating the role of A3AR in neuroinflammation, providing insights into its potential therapeutic implications in neurodegenerative conditions. Its high potency and selectivity make it a powerful tool for research involving adenosine receptor signaling pathways. -
A2B Antagonist
LAS38096 is a selective antagonist of the A2B adenosine receptor, exhibiting a high affinity with a Ki value of 17 nM. Through its inhibition of A2B receptor activity, LAS38096 has demonstrated significant potential in modulating adenosine-mediated biological processes. This compound is suitable for research applications related to inflammation, cancer, and cardiovascular diseases where adenosine signaling plays a critical role. -
A3 AR Antagonist
MRS542 is a nucleoside antagonist of the A3 adenosine receptor (A3 AR) with a pKi of 8.74. In addition to its antagonistic properties, MRS542 functions as a partial agonist, with an effective concentration (pEC50) of 7.76, promoting β-arrestin translocation. This compound is valuable for investigating the role of A3 AR in cardiovascular diseases and related research applications. -
Biochemical Assay Reagent
7-Methyladenosine perchlorate is a synthetic analog of adenosine that acts as an agonist at adenosine receptors. This compound effectively modulates cellular signaling pathways, making it a valuable reagent for investigating adenosine-related biological processes. Additionally, 7-Methyladenosine perchlorate holds potential as a tool in compound development, particularly as an inhibitor for biochemical assays. -
A2AAR Antagonist
LJ-4517 is a highly selective antagonist of the adenosine A2A receptor (A2AAR) with a binding affinity (Ki) of 18.3 nM. This compound effectively displaces the binding of [3H]ZM241385 at wild-type A2AAR, demonstrating its potency in modulating adenosine signaling pathways. Additionally, LJ-4517 features an alkyne moiety, enabling its use as a click chemistry reagent for copper-catalyzed azide-alkyne cycloaddition (CuAAc) applications. This dual functionality makes it a valuable tool for diverse biochemical research. -
A2A/A1 AR Antagonist
A2A/A1 AR antagonist-1 is a dual-target antagonist for the A2A and A1 adenosine receptors, exhibiting binding affinities (Kis) of 5.58 nM and 24.2 nM, respectively. It serves as a valuable tool for research related to ischemic stroke, providing insights into receptor interactions and potential therapeutic pathways. This compound is suitable for studies exploring adenosine receptor modulation in various biological contexts. -
A3AR Antagonist
A3AR antagonist 3 is a selective antagonist of the A3 adenosine receptor, exhibiting a Ki value of 37 nM. It demonstrates over 60-fold selectivity against A1 and A2A adenosine receptors. This compound is useful for investigating the role of A3AR in various biological processes and therapeutic applications, including inflammation and cancer research. -
Adenosine Receptor Antagonist
Bamifylline is a xanthine derivative that selectively antagonizes the adenosine A1 receptor. This compound is known to exhibit biological activities related to the modulation of adenosine signaling pathways, making it valuable for research in cardiovascular and neuroprotective studies. Its role as an adenosine receptor antagonist facilitates investigations into cellular responses mediated by adenosine, contributing to the understanding of various physiological and pathological processes. -
A1-adenosine Antagonist
(6R)-Naxifylline is a selective A1-adenosine antagonist that exhibits notable saluretic activity. This compound demonstrates the ability to induce relaxation of spontaneous tone in guinea pig trachea, making it a valuable tool for studying adenosine receptor pathways. Its unique pharmacological profile supports research applications in respiratory physiology and cardiovascular studies. -
Adenosine A3 Receptor Agonist
CP-608039 is a selective agonist for the adenosine A3 receptor, demonstrating potency in targeting this specific receptor. It has significant biological activity in studies related to ischemic myocardial injury, making it a valuable tool for researchers investigating cardiac protection and therapeutic interventions in ischemic conditions. Its unique mechanism of action allows for detailed exploration of adenosine-mediated pathways in cardiovascular research. -
A3AR Agonist
A3AR agonist 4 is a selective agonist of the A3 adenosine receptor (A3AR), exhibiting a Ki value of 1.24 nM for human A3AR. This compound effectively inhibits cyclic AMP (cAMP) production with an EC50 of 0.17 nM. A3AR agonist 4 is valuable for investigating mechanisms of inflammation and pain modulation in various biological studies. -
A3AR Modulator
MRS8247 is a positive allosteric modulator of the A3 adenosine receptor (A3AR), enhancing the receptor's activity and stability. This compound has been shown to slow the dissociation rate of agonists, thereby prolonging their biological effects. MRS8247 is valuable for research applications focused on adenosine signaling and its implications in physiological and pathological processes. -
Adenosine Receptor Antagonist
Zaladenant is an adenosine receptor antagonist predominantly targeting the A2A receptor subtype. This compound exhibits notable antitumor activity, making it relevant for investigations into cancer biology and treatment strategies. Its ability to modulate adenosine signaling pathways provides a valuable tool for research focused on tumor microenvironments and immune response. -
adenosine A3 receptor Antagonist
LJ-2698 is an orally active antagonist of the adenosine A3 receptor. This compound demonstrates significant anti-inflammatory effects by increasing levels of anti-inflammatory cytokines and promoting the proliferation of M2 macrophages in lung tissues, leading to improved pulmonary function and reduced alveolar cavity enlargement. Additionally, LJ-2698 has shown potential in preventing renal injury associated with diabetic nephropathy by inhibiting lipid accumulation and enhancing PGC1α expression in renal tissues. This reagent is suitable for research applications related to emphysema and diabetic nephropathy. -
A3AR PAM
A3AR Modulator 1 is a positive allosteric modulator (PAM) of the A3 adenosine receptor (A3AR). This compound significantly enhances the Cl-IB-MECA-stimulated [35S]GTPγS binding Emax, indicating its capacity to potentiate receptor activity. It is a valuable tool for research applications involving adenosine signaling pathways and may aid in the exploration of therapeutic targets related to inflammation, cancer, and neurodegenerative diseases. -
Adenosine Receptor Antagonist
ATL444 is a selective adenosine receptor antagonist that exhibits Ki values of 7.0 nM for the rA1AR receptor, 2.5 nM for rA2AAR, 61.8 nM for rA2BAR, and >1000 nM for rA3AR. This compound is valuable for research applications focused on the modulation of adenosine signaling pathways, which are implicated in various physiological processes and disease states. ATL444 can aid in elucidating the role of adenosine receptors in pharmacological studies, offering insights into their potential as therapeutic targets. -
Adenosine A2A Antagonist Prodrug
Lu AA47070 is a phosphonooxymethylene prodrug designed to selectively antagonize the Adenosine A2A receptor. It effectively reverses the motor and motivational impairments induced by dopamine D2 receptor antagonists. This compound is of particular interest in research focused on neuropsychiatric disorders and the interplay between dopaminergic and adenosinergic systems. -
A1AR Antagonist
A1AR antagonist 2 is a potent antagonist of the A1 adenosine receptor (A1AR), exhibiting inhibitory constants (Kis) of 1.49 nM for hA1, 10.2 nM for hA2A, and 50.1 nM for hA2B. This compound is valuable for research applications focused on the modulation of adenosine signaling pathways and their effects on physiological and pathological processes. Its selective inhibition of A1AR makes it a useful tool in pharmacological studies involving cardiovascular, neurological, and metabolic research. -
A1-AR Ligand
DU172 is a potent ligand for the adenosine A1 receptor (A1AR), exhibiting an IC50 of 24.9 nM. It also shows an affinity for the A2A receptor (A2AAR) with an IC50 of 0.42 μM. This compound is valuable for studies involving adenosine receptor signaling and can aid in research related to cardiovascular, neuroprotective, and anti-inflammatory mechanisms. -
A2aR Antagonist
A2A receptor antagonist 3 is a potent adenosine A2A receptor antagonist with a Ki of 0.4 nM. This compound also exhibits binding affinity for A2B, A1, and A3 receptors, with Ki values of 37 nM, 107 nM, and 1467 nM, respectively. It is valuable for research applications involving adenosine signaling pathways and pharmacological studies related to various physiological processes and diseases. -
Adenosine Receptor Antagonist
Lu AA41063 is an antagonist of the adenosine A2A receptor, exhibiting a Ki value of 5.9 nM for the human A2A receptor. This compound demonstrates potential therapeutic effects in the treatment of Parkinson's disease by modulating adenosine signaling pathways. It is a valuable reagent for research focused on neurodegenerative disorders and the pharmacological exploration of adenosine receptors. -
A2AR Antagonist
A2AR-antagonist-1 is a selective adenosine A2A receptor (A2AR) antagonist with an IC50 of 29 nM. This compound demonstrates significant anti-tumor activity and maintains metabolic stability in mouse liver microsomes (t1/2 = 86.1 min). Additionally, A2AR-antagonist-1 activates T cells by inhibiting immunosuppressive molecules such as LAG-3 and TIM-3, while promoting the expression of effector molecules including GZMB, IFNG, and IL-2, making it a valuable tool in cancer immunotherapy research. -
Adenosine Receptor Agonist
AMP-579 is an adenosine receptor agonist targeting the adenosine A1 and A2A receptors, exhibiting Ki values of 1.7 nM and 4.5 nM for A1 receptors in rat brain and adipocytes, and a Ki value of 56 nM for A2A receptors in rat brain. This compound effectively inhibits lipolysis and restores insulin-dependent glucose transport through A1 receptor activation, while it promotes vasodilation, especially in coronary arteries, via A2A receptor activation with an IC50 of 0.3 μM in porcine coronary arterial rings. AMP-579 holds potential in cardioprotection and the therapeutic management of acute myocardial infarction. -
Adenosine Receptor antagonist
1,9-Dimethylxanthine is an antagonist of adenosine receptors, effectively blocking adenosine's effects on the central nervous system. This compound enhances neuronal excitability through modulation of the adenosine signaling pathway. 1,9-Dimethylxanthine serves as a valuable pharmacological tool in research aimed at investigating physiological and pathological mechanisms associated with adenosine. -
α2 Receptor Agonist
p-Iodoclonidine hydrochloride is a partial agonist of the α2-adrenergic receptor, primarily influencing adrenergic signaling pathways. It exhibits low levels of adenylate cyclase inhibition in platelet membranes and enhances ADP-induced platelet aggregation with an EC50 of 1.5 μM. This compound is useful for research applications focusing on adrenergic receptor physiology and platelet function. -
A3AR Agonist
MRS5663 is a potent A3 adenosine receptor (A3AR) agonist, demonstrating an EC50 of 5.62 nM in β-arrestin2 recruitment assays. This compound exhibits significant cytoprotective effects, particularly in models of skeletal muscle ischemia-reperfusion injury and claudication. Its unique mechanism and biological activity make it a valuable tool for research in cardiovascular and metabolic disorders. -
Adenosine A2A Receptor Agonist
LASSBio-1359 is an agonist of the adenosine A2A receptor, known for its vasodilatory and anti-inflammatory properties. This compound has potential applications in cardiovascular research and the study of inflammatory diseases, making it a valuable tool in exploring adenosine receptor signaling pathways and their relevance to various physiological and pathological conditions. -
A3AR Agonist
A3AR Agonist 5 is a potent activator of the A3 adenosine receptor (A3AR), exhibiting EC50 and Ki values of 0.14 nM and 6.36 nM for cAMP and human A3 receptors, respectively. This compound is valuable for research into pain modulation and inflammation, making it a significant tool for studies examining adenosine receptor signaling pathways and their therapeutic implications. -
A2AR-D2R Heteromer Ligand
Heterobivalent ligand-1 is a potent heterobivalent ligand targeting the Adenosine A2A-dopamine D2 receptor heteromer, exhibiting binding affinities of 2.1 nM for A2AR and 0.13 nM for D2R. This compound is valuable for studying receptor heteromerization and signal transduction in neurological research. Its unique design enables exploration of the functional interplay between these receptors in various biological contexts.
